This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Clinical Trials
ADVISE
Adalimumab vs. Conventional Immunosuppression for Corticosteroid-sparing for Uveitis Trial
Overview
The ADVISE Trial is a randomised, parallel-treatment, comparative effectiveness trial.
It aims to compare the relative effectiveness of adalimumab compared to conventional immunosuppression at controlling ocular inflammation caused by uveitis, while permitting tapering and discontinuation of oral corticosteroids.
- Principal Investigator
Professor Lyndell Lim
The ADVISE Trial is a randomised, parallel-treatment, comparative effectiveness trial.
It aims to compare the relative effectiveness of adalimumab compared to conventional immunosuppression at controlling ocular inflammation caused by uveitis, while permitting tapering and discontinuation of oral corticosteroids.
- Principal Investigator
Learn more
View this study at ClinicalTrials.gov
This international database listing provides more detailed information about this study.